Targeting neutrophil extracellular traps with dornase alfa to reduce inflammation in chronic airway disease

Trial Profile

Targeting neutrophil extracellular traps with dornase alfa to reduce inflammation in chronic airway disease

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Acronyms NETs
  • Most Recent Events

    • 20 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top